Introduction
Chronic myeloid leukemia (CML) accounts for approximately 15–20% of all leukemias in adults1. CML is characterized by the BCR-ABL1 fusion gene encoding a constitutively active tyrosine kinase2. Tyrosine kinase inhibitor (TKI) can help to increase the survival time in CML patients; however, the risk of secondary malignancies due to TKIs is a growing concern. It is reported that second malignancies developed in 3.1–4.5% of case during the treatment course of CML, of which secondary lymphoma accounts for about 5%3-5. However, few reports showed clinical course of patients who developed lymphoma during TKI therapies. Herein, we report a case of high grade B-cell lymphoma (HGBCL) diagnosed in the course of CML treatment with bosutinib and present the review of literature.